Report cover image

Small Cell Lung Cancer - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 100 Pages
SKU # DEL19995341

Description

DelveInsight’s, “Small Cell Lung Cancer - Pipeline Insight, 2025,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Small Cell Lung Cancer Understanding

Small Cell Lung Cancer: Overview

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa. Symptoms of SCLC are chest pain, chronic cough, coughing up blood, difficulty breathing, facial swelling, fatigue, hoarseness, loss of appetite, swollen neck veins, weight loss, and wheezing. The standard treatment for first- and second-line management of small cell lung cancer (SCLC) is chemotherapy. Immunotherapy has also made progress in the treatment of SCLC including nivolumab, pembrolizumab, atezolizumab, and durvalumab.

""Small Cell Lung Cancer - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Small Cell Lung Cancer.
Small Cell Lung Cancer Emerging Drugs Chapters

This segment of the Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Small Cell Lung Cancer Emerging Drugs
  • AMG 757: Amgen
AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.
  • APG-1252: Ascentage Pharma
APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

Further product details are provided in the report……..

Small Cell Lung Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Small Cell Lung Cancer
There are approx. 100+ key companies which are developing the therapies for Small Cell Lung Cancer. The companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase III include, Ipsen.
  • Phases
DelveInsight’s report covers around 100+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Small Cell Lung Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Small Cell Lung Cancer drugs.

Small Cell Lung Cancer Report Insights
  • Small Cell Lung Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Small Cell Lung Cancer Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Small Cell Lung Cancer drugs?
  • How many Small Cell Lung Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Small Cell Lung Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Small Cell Lung Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Ascentage Pharma
  • Merck & Co
  • AstraZeneca
  • Advenchen Laboratories
  • GlaxoSmithKline
  • Advanced Accelerator Applications
  • Trillium Therapeutics
  • Vernalis
  • Oncoceutics
  • NewBio Therapeutics
  • Wigen Biomedicine
  • Linton Pharm
  • Carrick Therapeutics
  • Xencor
  • Jiangsu HengRui Medicine
  • Aileron Therapeutics
  • Roche
  • Ipsen
  • Celgene
  • Lee's Pharmaceutical Limited
  • AbbVie
  • G1 Therapeutics
  • Chipscreen Biosciences
  • Luye Pharma Group
  • Shanghai Henlius Biotech
  • CSPC ZhongQi Pharmaceutical Technology
  • Impact Therapeutics
Key Products
  • APG-1252
  • Pembrolizumab
  • Olaparib
  • Lucitanib
  • Dostarlimab
  • Lutetium-177 oxodotreotide
  • Ontorpacept
  • S 055746
  • ONC 201
  • NBT-558
  • WJ-05129
  • LP-003
  • Samuraciclib
  • XmAb18087
  • SHR3162
  • ALRN-6924
  • Irinotecan sucrosofate
  • CC-90011
  • Gimatecan
  • ABBV-011
  • G1T28
  • Chiauranib
  • LY01610
  • HLX10
  • PLM60
  • IMP4297

Table of Contents

100 Pages
Introduction
Executive Summary
Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pembrolizumab: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Dostarlimab: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AMG 757: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
S 055746: Vernalis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Small Cell Lung Cancer Key Companies
Small Cell Lung Cancer Key Products
Small Cell Lung Cancer- Unmet Needs
Small Cell Lung Cancer- Market Drivers and Barriers
Small Cell Lung Cancer- Future Perspectives and Conclusion
Small Cell Lung Cancer Analyst Views
Small Cell Lung Cancer Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us